Emily Malcolm, PhD,  —

Emily holds a Ph.D. in Biochemistry from the University of Iowa and is currently a postdoctoral scholar at the University of Wisconsin-Madison. She graduated with a Masters in Chemistry from the Georgia Institute of Technology and holds a Bachelors in Biology and Chemistry from the University of Central Arkansas. Emily is passionate about science communication, and, in her free time, writes and illustrates children’s stories.

Articles by Emily Malcolm

Soliris vs. Ultomiris for aHUS

Soliris (eculizumab) and Ultomiris (ravulizumab-cwvz) are medications developed by Alexion to treat atypical hemolytic uremic syndrome (aHUS). How are these medications similar? Both Soliris and Ultomiris contain humanized antibodies, or antibodies that work with the human immune system. These medications block the complement system, a…

FAQs About Soliris for aHUS

Soliris (eculizumab) is a medication developed by Alexion to treat atypical hemolytic uremic syndrome (aHUS). Here are some frequently asked question and answers about Soliris: How does Soliris work? In aHUS, a part of the immune system called the complement system becomes active when…

FAQs About Ultomiris for aHUS

Ultomiris (ravulizumab-cwvz) is a treatment for atypical hemolytic uremic syndrome (aHUS) that was developed by Alexion. The therapy is designed to treat people with low levels of circulating red blood cells. Here are some frequently asked question and answers about Ultomiris: How does it work? In…

Planning for the Future When You Have aHUS

Being diagnosed with a rare disease like atypical hemolytic uremic syndrome (aHUS) can be frightening, especially as this disease may affect your lifespan. Your care team will talk to you about the future. Many patients can also benefit from talking with a counselor. There are also local…

Clinical Trials for aHUS

Only a few treatment options exist for atypical hemolytic uremic syndrome (aHUS) and there’s currently no cure for the disease. One way that patients can help with the development of new and better treatments is by participating in clinical trials. What are clinical trials? Before pharmaceutical companies can…

How to Deal with aHUS Attacks

Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by the formation of small blood clots in the kidneys, blocking blood vessels, and causing damage that can lead to kidney failure. The disease also leads to anemia (low red blood cell counts) and thrombocytopenia…

FAQs About Dialysis in aHUS

Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by the formation of blood clots in the small blood vessels of the kidneys. The kidneys filter waste out of the blood, but blood clots may interfere with blood flow and prevent the kidneys from doing…